The mucopolysaccharidoses (MPSs) are a group of 11 storage diseases caused by disruptions in glycosaminoglycan (GAG) catabolism, leading to their accumulation in lysosomes. Resultant multisystemic disease is manifested by growth delay, hepatosplenomegaly, skeletal dysplasias, cardiopulmonary obstruction, and, in severe MPS I, II, III, and VII, progressive neurocognitive decline. Some MPSs are treated by allogeneic hematopoietic stem cell transplantation (HSCT) and/or recombinant enzyme replacement therapy (ERT), but effectiveness is limited by central nervous system (CNS) access across the blood-brain barrier. To provide a high level of gene product to the CNS, we tested neonatal intracerebroventricular (ICV) infusion of an adeno-associated virus (AAV) serotype 8 vector transducing the human α-L-iduronidase gene in MPS I mice. Supranormal levels of iduronidase activity in the brain (including 40× normal levels in the hippocampus) were associated with transduction of neurons in motor and limbic areas identifiable by immunofluorescence staining. The treatment prevented accumulation of GAG and GM3 ganglioside storage materials and emergence of neurocognitive dysfunction in a modified Morris water maze test. The results suggest the potential of improved outcome for MPSs and other neurological diseases when a high level of gene expression can be achieved by direct, early administration of vector to the CNS.
Introduction
The mucopolysaccharidoses (MPSs) are a group of 11 rare, recessive inherited disorders included within the larger family of more than 40 identified lysosomal storage diseases (LSDs). LSDs comprise approximately 14% of all inherited metabolic diseases and affect nearly 1:7700 births, of which~30% are MPSs (Meikle et al., 1999; Poorthuis et al., 1999) . MPSs are caused by mutations in genes that encode any of the lysosomal hydrolases responsible for the catabolism of GAGs. Genetic deficiency for any of these specific enzymes is associated with growth delay, organomegaly, cardiopulmonary disease, skeletal dysplasias, and obstructive airway disease (Neufeld and Muenzer, 2001) . Importantly, individuals with the most severe forms of MPS I, II, III, and VII suffer from severe neurological dysfunction and early death.
Although HSCT and ERT are currently used to treat MPSs, delivery of enzyme to the central nervous system (CNS) remains a major challenge due to the inability of lysosomal enzymes to efficiently cross the blood-brain barrier (Begley et al., 2008; Enns and Huhn, 2008) . Early intervention with HSCT has been emphasized for the prevention of cognitive decline in neuropathic MPSs (Boelens et al., 2009; Staba et al., 2004) . However, although neurological outcomes for several of the MPSs are improved with donor cell engraftment following HSCT, recipients continue to exhibit below normal IQ and impaired neurocognitive capability (Ziegler and Shapiro, 2007) . The aim of this study was to investigate the effects of providing a superior level of enzyme to the brain by direct infusion of an adeno-associated virus (AAV) vector in a murine model of Hurler syndrome (MPS I).
Both AAV2 and AAV5 vectors have been previously used to express lysosomal enzymes in the CNS and to reduce lysosomal GAG storage material following intraparenchymal infusion into mouse models of MPS I (Desmaris et al., 2004 ), MPS IIIB (Cressant et al., 2004 , and MPS VII (Bosch et al., 2000; Frisella et al., 2001; Liu et al., 2007) , as well as a dog model of MPS I (Ciron et al., 2006; Ellinwood et al., 2010) . In some cases, this has resulted in improved neurobehavior (Cressant et al., 2004; Frisella et al., 2001; Liu et al., 2007) . Since AAV8 vectors have been shown to more efficiently transduce neurons within the neonatal mouse brain than either AAV2 or AAV1 vectors (Broekman et al., 2006) , we generated an AAV8 vector expressing human α-Liduronidase (IDUA). This vector was infused into the lateral ventricles Neurobiology of Disease 43 (2011) 123-133 
